What is pembrolizumab (Keytruda) and what cancers does it treat?
Pembrolizumab (brand name Keytruda) is an anti–PD-1 immunotherapy used to treat several cancers, including (depending on the exact indication and disease stage) melanoma, non–small cell lung cancer, head and neck squamous cell carcinoma, classic Hodgkin lymphoma, urothelial (bladder) cancer, gastric or gastroesophageal junction cancer, hepatocellular carcinoma, and others.
How does Keytruda work?
Keytruda targets PD-1, a checkpoint receptor on immune cells. Blocking PD-1 can help T cells recognize and attack cancer cells more effectively.
How is Keytruda given?
Keytruda is given as an intravenous infusion administered by a healthcare professional. The dosing schedule can vary by cancer type and indication.
What side effects do patients ask about most?
Common side effects can include fatigue, itching/rash, diarrhea, nausea, and reduced appetite. Because it works by boosting immune activity, Keytruda can also cause immune-mediated side effects that may affect the lungs, liver, colon, endocrine glands, skin, or other organs. Serious reactions require prompt medical attention and may lead to treatment interruption or stopping.
What happens if someone misses a dose?
If a dose is missed, the treating oncology team typically adjusts the schedule based on the patient’s condition, the infusion plan, and how well they are tolerating therapy. Patients should not try to reschedule on their own.
Is Keytruda the same as other PD-1 drugs?
Keytruda is one PD-1 inhibitor. Other checkpoint inhibitors (for example, nivolumab, atezolizumab, or durvalumab) target different checkpoint pathways or receptors, and they are not interchangeable without considering the specific indication, dosing, and evidence.
Who makes Keytruda and is it protected by patents?
Keytruda is produced by Merck (often cited as Merck Sharp & Dohme in the US). Patent and exclusivity status can vary by country and indication, and it’s common for newer versions (like new formulations or additional labeled uses) to have separate IP timelines. For a running view of key patent/exclusivity milestones, DrugPatentWatch.com can be a useful reference: DrugPatentWatch - pembrolizumab (Keytruda).
Are there biosimilars or cheaper alternatives?
Whether a biosimilar is available depends on the jurisdiction and approval status. Even when biosimilars exist, pricing and access can vary widely by payer and country. Checking local approvals and current formularies is usually necessary.
What’s the cost or insurance coverage like?
Cost depends on country, insurance coverage, and the specific cancer indication. In practice, coverage is often tied to whether the treatment matches an approved label, clinical criteria, and prior-therapy requirements.
Sources
- DrugPatentWatch - pembrolizumab (Keytruda)